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NOT PRECEDENTIAL
UNITED STATES COURT OF APPEALS
FOR THE THIRD CIRCUIT
_____________
No. 19-2462
_____________
NAVIGATORS SPECIALTY INSURANCE COMPANY,
Appellant
v.
INVENTIV HEALTH CLINICAL, INC., f/k/a PHARMANET DEVELOPMENT
GROUP, INC.; INVENTIV CLINICAL, LLC, f/k/a PHARMANET, LLC
v.
LANDMARK AMERICAN INSURANCE COMPANY
______________
On Appeal from the United States District Court
for the District of New Jersey
(D.C. Civil No. 3-15-cv-06285)
District Judge: Honorable Peter G. Sheridan
______________
Submitted under Third Circuit L.A.R. 34.1(a)
July 1, 2020
____________
Before: GREENAWAY, JR., SHWARTZ, and RENDELL, Circuit Judges.
(Opinion Filed: September 8, 2020)
______________
OPINION ∗
______________

∗

This disposition is not an opinion of the full Court and pursuant to I.O.P. 5.7 does
not constitute binding precedent.

GREENAWAY, JR., Circuit Judge.
Despite its contentions to the contrary, Plaintiff-Appellant Navigators Specialty
Insurance Company (“Navigators”) had a duty to defend Defendants-Appellees inVentiv
Health Clinical, Inc. and inVentiv Clinical, LLC, f/k/a PharmaNet Development Group,
Inc. and PharmaNet, LLC (collectively “PharmaNet”) in an underlying arbitration dispute
(the “Underlying Arbitration”) based on the terms of a professional services liability
policy PharmaNet had purchased from Navigators. For the reasons provided below, we
will affirm the District Court’s Order entered on June 18, 2019. 1
I.

FACTUAL AND PROCEDURAL BACKGROUND

There are three key aspects to this appeal: (1) the insurance policy (the “Policy”)
purchased by PharmaNet from Navigators, (2) the claims made by CEL-SCI Corporation
(“CEL-SCI”) against PharmaNet in the Underlying Arbitration, 2 and (3) Navigators’s
assertion, after a professional malpractice claim was dismissed from the Underlying

1

The District Court’s Order, dated June 17, 2019 and entered on June 18, 2019,
CM/ECF No. 105, made final the District Court’s prior: (1) Memorandum and Order
entered on March 29, 2016 (“March 29 Order”) denying Navigators’s Motion for
Judgment on the Pleadings and granting PharmaNet’s Motion for Partial Summary
Judgment on Navigators’s duty to defend PharmaNet in the Underlying Arbitration, see
CM/ECF No. 29, (2) Order entered on March 1, 2017 (“March 1 Order”) granting
PharmaNet’s Motion to Enforce Judgment, see CM/ECF No. 69, and (3) Opinion on
insurance disbursement entered on February 22, 2017 (“February 22 Opinion”), see
CM/ECF No. 72. Navigators thus appeals from the March 29 Order, the March 1 Order,
and the February 22 Opinion, all of which were finalized by the Order entered on June
18, 2019. See J.A. 1.
2

We note at the outset that this case contains partially sealed briefs and records, so
as to protect arbitration-related materials. See Appellate Dkt. No. 29. To the extent we
must discuss the claims in the Underlying Arbitration, we will do so in generalized terms.
2

Arbitration, that the remaining claims were barred by an exclusion provision in the
Policy.
First, PharmaNet purchased a Life Sciences Products-Completed Operations and
Professional Services Liability Coverage Policy (i.e., the Policy) from Navigators. The
Policy provides, in part, “B. Professional Services Coverage,” which reads:
Subject to paragraph C. below, [Navigators] will pay all amounts in
excess of the deductible up to the limit of liability that [PharmaNet]
becomes legally obligated to pay as damages as a result of a covered
professional liability claim by reason of a wrongful act by
[PharmaNet] or by someone for whom [PharmaNet] is liable.
In addition, [Navigators] will pay all claim expenses in excess of the
deductible and up to the limit of liability. Claim expenses are included
within and erode both the limits of liability and the deductible.
Sealed J.A. 326 (certain emphasis omitted); see also J.A. 19–20. 3 The Policy also
contains, in part, an exclusion for “Performance Delay,” which states that
“Coverage A and B [i.e., Professional Services Coverage] do not apply to any claim
. . . based on or arising out of delay in delivery of or failure to complete your product
or your work[.]” Sealed J.A. 331 (emphasis omitted); see also Redacted Appellant’s
Br. 9.
Second, PharmaNet was hired by CEL-SCI as a professional contract research

3

A “[p]rofessional liability claim,” is that which “alleg[es] a wrongful act in the
rendering or failure to render professional services.” Sealed J.A. 340 (emphasis omitted);
see also Redacted Appellant Br. 8. A “[w]rongful act” is “any actual or alleged negligent
act, error or omission in the rendering of professional services by any Insured on your
behalf.” Sealed J.A. 341 (emphasis omitted); see also Redacted Appellant Br. 8.
“Professional services” includes that which is set forth in the “Professional Services
Endorsement,” which includes work as a contract research organization. Sealed J.A. 340,
364; see also Redacted Appellant Br. 8.
3

organization to aid with the management and administration of a clinical trial. CEL-SCI
initiated the Underlying Arbitration against PharmaNet alleging breach of contract, fraud
in the inducement, and common law fraud, and seeking damages, in part, for failures and
delays. In an amended statement of claim, CEL-SCI added a claim for professional
malpractice, however, this claim was ultimately dismissed by the arbitrator as duplicative
of the breach of contract claim found in the original statement of claim.
Third, while Navigators initially agreed to defend PharmaNet in the Underlying
Arbitration, after the professional malpractice claim was dismissed, Navigators
disclaimed coverage. Navigators argued that the remaining claims were based on delays,
which fell under the Policy’s exclusion provision.
Navigators then filed a complaint in the District Court for declaratory relief,
“seek[ing] a declaration that it has no duty to defend or indemnify PharmaNet in” the
Underlying Arbitration based on the Policy’s delay exclusion. Sealed J.A. 45. After
PharmaNet filed an answer and counterclaim, and Navigators filed a motion for judgment
on the pleadings, which PharmaNet opposed, cross-moving for partial summary
judgment, the District Court granted PharmaNet’s motion for partial summary judgment
on the duty to defend issue and denied Navigators’s motion for judgment on the
pleadings. 4 Once the District Court entered partial final judgment certifying that “the

4

Additionally, after the District Court’s March 29 Order, PharmaNet filed a
motion to enforce judgment, which was granted and discussed in the March 1 Order and
the February 22 Opinion, and finalized in the June 18, 2019 Order. Navigators’s
appellate briefing is concerned only with whether, as a matter of law, it had a duty to
defend or whether the exclusion applied. See generally Redacted Appellant Br. 21–22.
4

parties’ claims regarding Navigators’ duty to defend [PharmaNet] in the underlying
arbitration have been fully and finally adjudicated on the merits by way of the following
Orders[,]” J.A. 3–4, Navigators filed a timely notice of appeal. 5
II.

JURISDICTION AND STANDARD OF REVIEW

The District Court had jurisdiction pursuant to 28 U.S.C. § 1332, and we have
jurisdiction pursuant to § 1291. We review both a district court’s grant of summary
judgment ruling and its denial of judgment on the pleadings de novo. See, e.g., Dwyer v.
Cappell, 762 F.3d 275, 279 (3d Cir. 2014); Sikirica v. Nationwide Ins. Co., 416 F.3d 214,
219 (3d Cir. 2005). A grant of summary judgment is appropriate when “the movant
shows that there is no genuine dispute as to any material fact and the movant is entitled to
judgment as a matter of law.” Dwyer, 762 F.3d at 279 (quoting Fed. R. Civ. P. 56(a)). A
motion for judgment on the pleadings “will not be granted unless the movant clearly
establishes there are no material issues of fact, and he is entitled to judgment as a matter
of law.” Sikirica, 416 F.3d at 220. “Interpretation of an insurance policy is a question of
law,” which we review de novo. Id.
III.

ANALYSIS

The District Court was correct in finding that, as a matter of law, Navigators had a
duty to defend PharmaNet in the Underlying Arbitration, as at least some of CEL-SCI’s
damages claims were predicated on performance failures, existing separate and apart

5

Though Landmark American Insurance Company appears on the case caption,
the company was dismissed as a defendant from this case on May 2, 2019. See CM/ECF
No. 103.
5

from delays, such that the Policy’s delay exclusion did not exempt Navigators from its
duty to defend (i.e., there were allegations made by CEL-SCI that were covered and not
excluded by the Policy).
As the District Court noted, “New Jersey law controls in this case,” J.A. 9, and
under New Jersey law, an insurance company has a duty to defend when an underlying
complaint against the insured “states a claim constituting a risk insured against.”
Voorhees v. Preferred Mut. Ins. Co., 607 A.2d 1255, 1259 (N.J. 1992) (citation omitted).
The duty to defend is “determined by comparing the allegations in the complaint with the
language of the policy . . . [and it] arises, irrespective of the claim’s actual merit. If the
complaint is ambiguous, doubts should be resolved in favor of the insured and thus in
favor of coverage.” Id. (internal citation omitted); see also Abouzaid v. Mansard
Gardens Assocs., LLC, 23 A.3d 338, 346 (N.J. 2011) (“As a practical matter, the
determination of an insurer’s duty to defend requires review of the complaint with
liberality to ascertain whether the insurer will be obligated to indemnify the insured if the
allegations are sustained” (citation and internal quotation marks omitted)). If a complaint
contains multiple alternative causes of action, “the duty to defend will continue until
every covered claim is eliminated.” Voorhees, 607 A.2d at 1259; see also Hofing v. CNA
Ins. Cos., 588 A.2d 864, 867–68 (N.J. Super. Ct. App. Div. 1991) (“If the pleadings state
facts bringing the injury within the coverage of the policy, the insurer must defend
regardless of the insured’s ultimate liability to the complainant. . . . The nature of the
damage claim . . . determines whether the insurer is obliged to defend.”).
Here, in the Underlying Arbitration, CEL-SCI’s statement of claim and amended
6

statement of claim contained multiple allegations. Though Navigators believes the
allegations of failures alleged by CEL-SCI “were inseparable from PharmaNet’s delays
and its ultimate failure to complete,” Redacted Appellant Br. 11, we disagree. The delays
and failures alleged by CEL-SCI are not all inexorably intertwined, indeed, there are
instances where CEL-SCI alleged failures by PharmaNet that appear to exist separate and
apart from allegations of delays and the failure to complete. See, e.g., Voorhees, 607
A.2d at 1259 (resolving ambiguities and doubts in a complaint in favor of the insured).
As such, the claims made by CEL-SCI can be read as including references to both delays
and failures that exist separately from one another. See, e.g., Sealed J.A. 140–141 ¶¶ 1516, 155 ¶ 68, 218 § IX, 237 ¶ 369, 248 ¶ 416; but see, e.g., Sealed 254 ¶ 434. Further,
though one of CEL-SCI’s claims was dismissed—a claim for professional malpractice—
it was noted as being essentially duplicative of allegations that remained. See Sealed J.A.
451. Thus, having considered the underlying allegations by CEL-SCI, and finding that
there were claims related to performance failures, existing separate and apart from the
delays—i.e., not just existing as but-for causation for the delays, see, e.g., Robert W.
Hayman, Inc. v. Acme Carriers, Inc., 696 A.2d 1125, 1127–29 (N.J. Super. Ct. App. Div.
1997)—we turn to the Policy itself to see if any claims are covered.
The Policy provides coverage for “wrongful act[s],” Sealed J.A. 326 (emphasis
omitted), defined as “actual or alleged negligent act[s], error[s] or omission[s] in the
rendering of professional services,” Sealed J.A. 341 (emphasis omitted), i.e., services
performed by PharmaNet in its role as a contract research organization. See Sealed J.A.
340, 364. This language is plain and unambiguous. See Voorhees, 607 A.2d at 1260.
7

The Policy also includes an exclusion barring coverage for professional liability claims
due to wrongful acts “based on or arising out of delay in delivery of or failure to
complete your product or your work[.]” Sealed J.A. 331 (emphasis omitted). This
exclusion is likewise clear, exempting Navigators from having to provide coverage for
wrongful acts “based on or arising out of” PharmaNet’s potential delays or failure to
complete. Id.; see also Princeton Ins. Co. v. Chunmuang, 698 A.2d 9, 17 (N.J. 1997)
(explaining that exclusions are also “given effect if specific, plain, clear, prominent, and
not contrary to public policy” (citation and internal quotation marks omitted)).
Navigators thus argues that this delay exclusion exempts it from defending
PharmaNet in the Underlying Arbitration because the underlying claims were based on or
arose out of a delay or failure to complete. Though “[t]he phrase ‘arising out of’ has been
defined broadly in other insurance coverage decisions to mean conduct ‘originating
from,’ ‘growing out of’ or having a ‘substantial nexus’ with the activity for which
coverage is provided,” Princeton Ins. Co., 698 A.2d at 16 (citation omitted), “exclusions
must be narrowly construed,” and “the burden is on the insurer to bring the case within
the exclusion,” id. at 16–17. See also S.T. Hudson Eng’rs, Inc. v. Pa. Nat. Mut. Cas. Co.,
909 A.2d 1156, 1163 (N.J. Super. Ct. App. Div. 2006) (noting that the burden is on the
insured to show a claim falls under a policy). Here, it is evident that at least some of
CEL-SCI’s claims are related to PharmaNet’s alleged delays. See J.A. 10 (referencing
and providing examples of CEL-SCI’s claims that detail alleged delays). Indeed, there
are instances where CEL-SCI’s claims could reasonably be read as suggesting delays
arising from PharmaNet’s mismanagement. See, e.g., Sealed J.A. 249 ¶ 418, 251 ¶ 424,
8

252 ¶ 429, 254 ¶ 434. However, there are also claims that purely allege failures to
perform tasks as required by the contract. See, e.g., Sealed J.A. 252 ¶¶ 427, 428, 253 ¶¶
430, 431.
Thus, given the ambiguities in the complaint—namely, whether CEL-SCI sought
damages due solely to delays, for delays caused by wrongful acts, or for both wrongful
acts and delays—it was correct of the District Court pursuant to New Jersey law to read
the complaint liberally in favor of PharmaNet. See J.A. 11–12 (citing the Amended
Statement of Claim, ¶ 416, which mentions “delays and failures” (emphasis added)); see
also Abouzaid, 23 A.3d at 346; Voorhees, 607 A.2d at 1259.
CEL-SCI’s allegations and claims include, at the very least, both claims of delays
and claims of failures, which can be read independently at times. See, e.g., Salem Grp. v.
Oliver, 607 A.2d 138, 140 (N.J. 1992) (holding that when a complaint can be read as
alleging concurrent causation, the insurer “must honor its duty to defend”). Thus, while
the Policy contained a valid exclusion, Princeton Ins., 698 A.2d at 17, there were
underlying claims that did not fall into the Policy’s exclusion and remain covered under
the Policy, Voorhees, 607 A.2d at 1259, such that Navigators had a duty to defend. 6
IV.

CONCLUSION

For the reasons set forth above, we will affirm the Order entered by the District
Court on June 18, 2019, which finalized two prior orders and one oral decision, from
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Having found that Navigators had a duty to defend, we need not reach the
question of whether the Policy’s exclusion was illusory. See, e.g., Redacted Appellant
Br. 41.
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March 29, 2016, March 1, 2017, and February 22, 2017.

10

